Table 3.
PMs that are clinically approved and undergoing clinical trials [112].
| S.No. | PM | Excipient | Drug Release | Therapeutic Agent | Disease Type | NCT Number/ Clinical Phase (Status) |
|---|---|---|---|---|---|---|
| 1 | Genexol-PM | PEG-b-PLA | Controlled release with no specific triggering mechanism | PTX | Breast Cancer | NCT00876486/Phase III (Completed) |
| PTX, PM with DOX | Metastatic Breast Cancer | NCT01784120/Phase II (Unknown) | ||||
| PTX | Recurrent Breast Cancer | NCT00912639/Phase IV (Unknown) | ||||
| PTX | Breast Cancer | NCT01169870/Phase II (Withdrawn) | ||||
| PTX, PM with Carboplatin | Ovarian Cancer |
NCT00877253/ Phase I (Completed) |
||||
| 2 | NK105 | PEG-b-PPBA | Sustained release equivalent dose of <1 μg mL−1 with no specific triggering mechanism | PTX | Metastatic or Recurrent Breast Cancer |
NCT01644890/ Phase III (Completed) |
| 3 | Nanoxel-PM | PEG-PDLLA | DTX was released immediately from micelle to bind to the plasma proteins. Pharmacokinetics equivalent to Taxotere® | DTX | Breast Cancer, Non-small Cell Lung Cancer | NCT04066335/(Recruiting) |
| No specific triggering mechanism | PTX | Advanced Breast Cancer |
NCT00915369/ Phase I(Unknown) |
|||
| 4 | Docecal | XR-17 block polymer | Controlled release with no specific triggering mechanism | DTX | Breast Cancer | 2012-005161-12 (EudraCT)/Phase III (results not published) |
| 5 | NK012 | PEG-b-poly(glutamate) | Releases SN-38 under neutral conditions even without the presence of a hydrolytic enzyme | SN-38 an active metabolite of irinotecan hydrochloride (CPT-11) | Triple Negative Breast Cancer | NCT00951054/Phase II/Completed |
| Releases SN-38 under neutral conditions | NK012 and Carboplatin | Metastatic Triple Negative Breast Cancer | NCT01238952/Phase 1/Completed |